SADC China UNAIDS Pharmaceutical Manufacturing Pact
Analysis based on 9 articles · First reported Sep 01, 2026 · Last updated Sep 16, 2026
The initiative signals a long-term shift toward local pharmaceutical production in Southern Africa, which could gradually reduce import dependence and create new investment and partnership opportunities for Chinese and African drugmakers. Near-term market impact is limited, but it supports a positive sentiment for healthcare and pharmaceutical sector participants exposed to Africa-China cooperation.
UNAIDS, the Southern African Development Community (SADC) and the Global Health Innovation Institute (GHII) have brought together the Government of South Africa, the Government of China, Chinese pharmaceutical companies and regional and global partners in a new collaboration to strengthen pharmaceutical manufacturing across Southern Africa. The partnership was advanced through a SADC-China strategic exchange held from 31 August to 4 September 2026 in Johannesburg, Durban and Cape Town, where delegations visited pharmaceutical and vaccine manufacturing, biotechnology, genomics and diagnostics facilities. Following the exchange, the partners agreed to advance technology transfer, skills development and investment opportunities to expand local pharmaceutical manufacturing capacity, reduce reliance on imports and strengthen health security. Priority areas identified include developing a regional list of essential HIV and sexual and reproductive health commodities, strengthening demand forecasting and pooled procurement, creating more predictable markets for African manufacturers, and supporting regulatory systems for quality-assured production. The collaboration aligns with the United Nations Political Declaration on HIV/AIDS and efforts to end AIDS as a public health threat by 2030. UNAIDS officials including Regional Director Anne Githuku-Shongwe and Eva Kiwango of the UNAIDS Office in China, SADC Secretariat representative Dr Lamboly Kumboneki, GHII's Gary Yang, an official from China's United States — Centers for Disease Control and Prevention, and Desano Pharmaceutical Group CEO Xiaoxia An all voiced support for the initiative.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard